According to a new report from Intel Market Research, the global Adalimumab Market was valued at USD 141 million in 2024 and is projected to reach USD 195 million by 2034, growing at a CAGR of 4.9% during the forecast period (2025–2034). This growth is primarily driven by the increasing prevalence of autoimmune diseases and expanding treatment indications for adalimumab.
What is...